Trial Profile
A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib at a Dose at 400 - 600 mg/d.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms START-R
- Sponsors Bristol-Myers Squibb
- 01 Aug 2017 Results evaluating cardiovascular ischaemic event rates in dasatinib treated patients using patient data from NCT00103701, NCT00101647, NCT00101816, NCT00101660, NCT00101595, NCT00103844, NCT00123474, NCT00123487, NCT00481247, NCT00529763, NCT01357655, NCT00744497 trials and and comparing it with external reference populations published in the Annals of Hematology
- 02 Nov 2012 Planned number of patients changed from 150 to 180.
- 15 Sep 2009 Two-year follow-up results published in Cancer.